ZA200609021B - Novel use of peptide compounds for treating essential tremor and other tremor syndromes - Google Patents

Novel use of peptide compounds for treating essential tremor and other tremor syndromes

Info

Publication number
ZA200609021B
ZA200609021B ZA200609021A ZA200609021A ZA200609021B ZA 200609021 B ZA200609021 B ZA 200609021B ZA 200609021 A ZA200609021 A ZA 200609021A ZA 200609021 A ZA200609021 A ZA 200609021A ZA 200609021 B ZA200609021 B ZA 200609021B
Authority
ZA
South Africa
Prior art keywords
tremor
peptide compounds
novel use
syndromes
treating essential
Prior art date
Application number
ZA200609021A
Other languages
English (en)
Inventor
Stohr Thomas
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Publication of ZA200609021B publication Critical patent/ZA200609021B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA200609021A 2004-06-24 2006-10-30 Novel use of peptide compounds for treating essential tremor and other tremor syndromes ZA200609021B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58208404P 2004-06-24 2004-06-24

Publications (1)

Publication Number Publication Date
ZA200609021B true ZA200609021B (en) 2008-04-30

Family

ID=34970895

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200609021A ZA200609021B (en) 2004-06-24 2006-10-30 Novel use of peptide compounds for treating essential tremor and other tremor syndromes

Country Status (19)

Country Link
US (1) US7427601B2 (xx)
EP (1) EP1758606A1 (xx)
JP (1) JP5038892B2 (xx)
KR (1) KR20070034477A (xx)
CN (1) CN1964733B (xx)
AR (1) AR049940A1 (xx)
AU (1) AU2005256468B2 (xx)
BR (1) BRPI0512622A (xx)
CA (1) CA2566301C (xx)
EA (1) EA013592B1 (xx)
IL (1) IL179732A0 (xx)
MX (1) MXPA06015010A (xx)
MY (1) MY146509A (xx)
NO (1) NO20070423L (xx)
NZ (1) NZ551207A (xx)
TW (1) TWI361693B (xx)
UA (1) UA88166C2 (xx)
WO (1) WO2006000397A1 (xx)
ZA (1) ZA200609021B (xx)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60120104T2 (de) * 2001-03-20 2006-09-21 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
PT1243263E (pt) * 2001-03-21 2003-03-31 Sanol Arznei Schwarz Gmbh Nova utilizacao de uma classe peptidica de composto para o tratamento de alodinia ou de outros tipos diferentes de dor cronica ou fantasma
KR20060111524A (ko) * 2003-12-02 2006-10-27 쉬바르츠파르마에이지 펩타이드 화합물들의 중추 신경병증성 통증 치료를 위한신규한 용도
EP1579858A1 (en) * 2004-03-26 2005-09-28 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in painful diabetic neuropathy
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
US8008351B2 (en) 2004-04-16 2011-08-30 Ucb Pharma Gmbh Methods for prophylaxis or treatment of conditions associated with cortical spreading depression
EP1604655A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
EP1781276B1 (en) * 2004-08-27 2010-06-23 UCB Pharma GmbH Use of peptide compounds for treating bone cancer pain, chemotherapy- and nucleoside-induced pain
EP1642889A1 (en) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
US7902401B2 (en) * 2006-12-14 2011-03-08 Nps Pharmaceuticals, Inc. Fluorinated compounds
CN101466390B (zh) 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
EA027836B1 (ru) * 2006-06-15 2017-09-29 ЮСиБи ФАРМА ГМБХ Фармацевтическая комбинация для профилактики, облегчения и/или лечения приступов эпилепсии и ее применение
CA2672494A1 (en) * 2006-12-14 2008-06-19 Nps Pharmaceuticals, Inc. Use of d-serine derivatives for the treatment of anxiety disorders
US7747551B2 (en) * 2007-02-21 2010-06-29 Neurovista Corporation Reduction of classification error rates and monitoring system using an artificial class
US8933065B2 (en) * 2008-04-01 2015-01-13 The University Of North Carolina At Chapel Hill N-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents
US20110281808A1 (en) * 2010-05-14 2011-11-17 Allmax Nutrition Inc. Composition and Method for Increasing Pre Workout Thermogenics
EP2468261A1 (en) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide
US20130251813A1 (en) 2010-12-02 2013-09-26 Ucb Pharma Gmbh Formulation of lacosamide
EP4233861A3 (en) * 2016-08-11 2023-10-11 Ovid Therapeutics, Inc. Compositions for treatment of essential tremor

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378729A (en) * 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5773475A (en) * 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
US6277825B1 (en) * 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
US6589994B1 (en) 1996-08-30 2003-07-08 Nps Pharmaceuticals, Inc. Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
US6197764B1 (en) * 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
DE60112766T2 (de) * 2000-08-17 2006-03-30 Teva Pharmaceutical Industries Ltd. Verwendung von Derivaten der Valproinsäureamide und 2-Valproinsäureamide zur Behandlung und Prävention von Schmerzen und/oder Kopfschmerzen
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
PT1486206E (pt) 2000-08-25 2008-01-25 Res Corp Technologies Inc ¿utilizações para aminoácidos anticonvulsivantes para o tratamento de perturbações bipolares¿
ATE397584T1 (de) 2000-11-21 2008-06-15 Ucb Pharma Sa N-alkylierte gaba verbindungen, verfahren zu deren herstellung und deren verwendung als arzneimittel
AU2002245486B2 (en) * 2001-02-23 2006-11-16 Ucb Pharma, S.A. Treatment of tics, tremors and related disorders
DE60120104T2 (de) 2001-03-20 2006-09-21 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
PT1243263E (pt) 2001-03-21 2003-03-31 Sanol Arznei Schwarz Gmbh Nova utilizacao de uma classe peptidica de composto para o tratamento de alodinia ou de outros tipos diferentes de dor cronica ou fantasma
TWI312285B (en) * 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6828462B2 (en) * 2001-11-07 2004-12-07 Merz Pharma Gmbh & Co. Kgaa Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
AU2003283958A1 (en) * 2002-09-13 2004-04-30 Elan Pharmaceuticals, Inc. Method of treating tremors
EP1601691B1 (en) 2002-11-18 2008-01-16 BioProspecting NB Inc. Shrew paralytic peptide for use in neuromuscular therapy
US20050227961A1 (en) * 2004-04-08 2005-10-13 Vela Pharmaceuticals, Inc. Compositions and methods for treatment of neuropathic pain, fibromyalgia and chronic fatigue syndrome
EP1604654A1 (en) * 2004-05-18 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating dyskinesia
EP1604656A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)

Also Published As

Publication number Publication date
AU2005256468A1 (en) 2006-01-05
MY146509A (en) 2012-08-15
EA013592B1 (ru) 2010-06-30
JP2008503533A (ja) 2008-02-07
BRPI0512622A (pt) 2008-03-25
AU2005256468B2 (en) 2010-12-09
CN1964733A (zh) 2007-05-16
EA200700108A1 (ru) 2007-06-29
AR049940A1 (es) 2006-09-13
US20050288234A1 (en) 2005-12-29
EP1758606A1 (en) 2007-03-07
CA2566301C (en) 2011-06-14
NO20070423L (no) 2007-03-22
UA88166C2 (ru) 2009-09-25
IL179732A0 (en) 2007-05-15
KR20070034477A (ko) 2007-03-28
US7427601B2 (en) 2008-09-23
NZ551207A (en) 2010-07-30
JP5038892B2 (ja) 2012-10-03
TWI361693B (en) 2012-04-11
MXPA06015010A (es) 2007-03-26
CN1964733B (zh) 2012-05-23
TW200603823A (en) 2006-02-01
WO2006000397A1 (en) 2006-01-05
CA2566301A1 (en) 2006-01-05

Similar Documents

Publication Publication Date Title
ZA200609021B (en) Novel use of peptide compounds for treating essential tremor and other tremor syndromes
IL181896A0 (en) Methods and compositions for the treatment of hyperlipidemia
ZA200801253B (en) Novel use of peptide compounds for treating muscle pain
HK1152474A1 (en) Methods and compositions for the prevention and treatment of sepsis
IL178996A0 (en) Thienopyridinone compounds and methods of treatment
HK1100483A1 (en) 1-benzoyl-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses
EP1744744A4 (en) BIOACTIVE COMPOUNDS AND METHODS OF USE THEREOF
IL178860A (en) Certain chemical entities, preparations and processes
ZA200704677B (en) Compositions and methods for the treatment of autism
EP1773369A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHOD FOR THE PEPTIDE TREATMENT
IL185546A0 (en) N - (n - sulfonylaminomethyl) cyclopropanecarboxamide derivatives useful for the treatment of pain
IL182643A0 (en) Novel composition and methods for the treatment of immune related diseases
IL182436A0 (en) Thienopyridinone compounds and methods of treatment
ZA200703087B (en) Methods and compositions for the treatment of hyperlipidemia
IL178591A0 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
EP1786265A4 (en) NEW COMPOSITIONS AND PROCESSING METHODS
EP1720563A4 (en) METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION
IL187405A0 (en) Methods and compositions for the treatment of pain
PL1812797T3 (pl) Kompozycje i sposoby do leczenia chorób hiperproliferacyjnych i zapobiegania tym chorobom
EP1976551A4 (en) COMPOSITIONS COMPRISING COMPLEX PROTEIN CRYSTALS BY POLYCATIONS AND PROCESSING METHOD THEREOF
EP1962882A4 (en) COMPOSITIONS AND METHOD FOR TREATING DIABETES
ZA200710476B (en) Methods and compositions for the treatment of pain
IL185691A0 (en) Novel compounds derived from 5-thioxylose and therapeutic use thereof
GB0408521D0 (en) Treatment of sepsis
IL181762A0 (en) Methods of treating symptoms of multiple sclerosis using vitamin d and related compounds